Meditech begins second stage of Phase II
Monday, 06 December, 2004
Meditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.
The trial will examine the safety and efficacy of HyCAMP and compare it to irinotecan alone in 86 patients previously treated with 5-fluorouracil. The trial is expected to be completed in mid-2006.
In an earlier uncontrolled study testing HyCAMP in twelve patients, the treatment showed similar efficacy with improved safety.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
